Jiangxi Rimag Group Co., Ltd. Class H (HK:2522) has released an update.
Jiangxi Rimag Group Co., Ltd., a leader in medical imaging services in China, reported a significant year-on-year decline in revenue, gross profit, and profits for the first half of 2024, attributed to a slowdown in demand and stringent industry regulations. Despite these challenges, the company maintained stable core service revenue and continued to expand, including the listing of its H Shares on the Stock Exchange and extending its imaging center network. The Group also pioneered industry standards, releasing a new medical imaging examination standard to enhance data service quality and standardization.
For further insights into HK:2522 stock, check out TipRanks’ Stock Analysis page.